Working with TipRanks
Follow Us
Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Calendars
Economic Indicators
Calculators
Education
About Us
Working with TipRanks
Follow Us
Repligen Corp (RGEN)
NASDAQ:RGEN
Holding RGEN?
Track your performance easily
RGEN Stock Chart & Stats
Day’s Range$0 - $0
52-Week Range$110.45 - $211.13
Previous Close$140
Volume645.44K
Average Volume (3M)892.99K
Market Cap
$7.84B
Enterprise Value$7.77B
Total Cash (Recent Filing)$809.15M
Total Debt (Recent Filing)$742.85M
Price to Earnings (P/E)―
Beta1.51
Next Earnings
Oct 29, 2024EPS Estimate
$0.33Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.04
Shares Outstanding56,006,498
10 Day Avg. Volume807,063
30 Day Avg. Volume892,994
Standard Deviation0.13
R-Squared0.15
Alpha0.00401
Financial Highlights & Ratios
Price to Book (P/B)3.95
Price to Sales (P/S)13.02
Price to Cash Flow (P/CF)46.50
P/FCF Ratio51.60
Enterprise Value/Market CapN/A
Enterprise Value/Revenue12.91
Enterprise Value/Gross Profit27.29
Enterprise Value/Ebitda131.72
Forecast
1Y Price Target
$195.22Price Target Upside43.13% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering10
Repligen News
PremiumCompany Announcements
Repligen Issues Update on Restatement and Maintains Revenue GuidanceBulls Say, Bears Say
Bulls Say
Acquisitions And GrowthRepligen announced the acquisition of Tantti which strengthens the Proteins and Chromatography Franchise alongside new product launches.
Market RecoveryPharma is the farthest along in its recovery with strength seen for 3 quarters and the market largely back to normal spending patterns.
Revenue And GrowthRepligen's encouraging 2Q results support a return to above market growth in 2H24 and 2025, alongside an improving market environment and better visibility in the business.
Bears Say
Bioprocessing Recovery ConcernsConcerns about bioprocessing recovery, especially following recent BIO conference where participants signaled a slower-than-hoped recovery in bioprocessing.
China Market PerformanceRepligen expects US/EU bioprocessing to struggle in regaining market share in China due to strong local competition and government support for Chinese firms.
Revenue GuidanceRepligen lowered the midpoint of its revenue guidance by (1%) due to continued softness in China but maintained the full year revenue guide ex-China.
---
Risk Analysis
Main Risk Category
Finance & CorporateFinancial and accounting risks. Risks related to the execution of corporate activity and strategy
RGEN FAQ
What was Repligen Corp’s price range in the past 12 months?
Repligen Corp lowest stock price was $110.45 and its highest was $211.13 in the past 12 months.
What is Repligen Corp’s market cap?
Currently, no data Available
When is Repligen Corp’s upcoming earnings report date?
Repligen Corp’s upcoming earnings report date is Oct 29, 2024 which is in 41 days.
How were Repligen Corp’s earnings last quarter?
Repligen Corp released its earnings results on Jul 30, 2024. The company reported $0.33 earnings per share for the quarter, beating the consensus estimate of $0.326 by $0.004.
Is Repligen Corp overvalued?
According to Wall Street analysts Repligen Corp’s price is currently Undervalued.
Does Repligen Corp pay dividends?
Repligen Corp does not currently pay dividends.
What is Repligen Corp’s EPS estimate?
Repligen Corp’s EPS estimate is $0.33.
How many shares outstanding does Repligen Corp have?
Repligen Corp has 56,006,496 shares outstanding.
What happened to Repligen Corp’s price movement after its last earnings report?
Repligen Corp reported an EPS of $0.33 in its last earnings report, beating expectations of $0.326. Following the earnings report the stock price went up 16.37%.
Which hedge fund is a major shareholder of Repligen Corp?
Among the largest hedge funds holding Repligen Corp’s share is Sands Capital Management LLC. It holds Repligen Corp’s shares valued at 179M.
---
Repligen Stock Smart Score
Unlock Smart Score
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$195.22 (43.13% Upside)
$195.22 (43.13% Upside)
Blogger Sentiment
Neutral
RGEN Sentiment 50%
Sector Average 71%
Sector Average 71%
Hedge Fund Trend
Decreased
By 86.0K Shares
Last Quarter.
Last Quarter.
Insider Transactions
Sold Shares
Worth $5.1M over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Neutral
Last 7 Days ▼ 1.4%
Last 30 Days ▲ 2.1%
Last 30 Days ▲ 2.1%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-15.40%
12-Months-Change
Fundamentals
Return on Equity
-0.10%
Trailing 12-Months
Asset Growth
12.28%
Trailing 12-Months
Company Description
Repligen Corp
Repligen Corp. provides advanced bioprocessing technologies and solutions used in the process of manufacturing biologic drugs. The firm serves through the following product lines: Chromatography; Filtration; and OEM Products (Proteins). The Chromatography product line includes a number of products used in the downstream purification and quality control of biological drugs. The Filtration products offer a number of advantages to manufacturers of biologic drugs at volumes that span from pilot studies to clinical and commercial-scale production. The OEM products are represented by Protein A affinity ligands, which are a critical component of Protein A chromatography resins used in downstream purification, and cell culture growth factor products. The company was founded by Alexander G. Rich and Paul R. Schimmel in May 1981 and is headquartered in Waltham, MA.
---
RGEN Earnings Call
Q2 2024
0:00 / 0:00
---
RGEN Revenue Breakdown
99.94% Product revenue
0.06% Royalty and other income
---
RGEN Stock 12 Month Forecast
Average Price Target
$195.22
▲(43.13% Upside)
Technical Analysis
Best Analysts Covering RGEN
1 Year
1 Year Success Rate
11/19 ratings generated profit
1 Year Average Return
+23.00%
reiterated a buy rating last month
Copying Daniel Arias's trades and holding each position for 1 Year would result in 57.89% of your transactions generating a profit, with an average return of +23.00% per trade.
---